Celecoxib

CAS 169590-42-5 36 current records 3 historicalSmall Molecule

Who holds supplier records for Celecoxib? 36 organisations hold a current record for Celecoxib: an active US FDA Type II Drug Master File or a CEP. A further 3 organisations have only historical (inactive) DMF filings. 26 of them hold a valid EU Certificate of Suitability (28 holder entries on the EDQM register, listed below). Recorded organisation countries for current records: India (22), China (8), Peru (1), Taiwan (1) and 3 other countries (3); not recorded for 1.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Celecoxib: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/celecoxib

Reading the evidence

  • 36 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    22 of the 35 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 20 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Celecoxib expires 17 Sept 2045. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (36)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Celecoxib. Country is the organisation's recorded country, not necessarily the manufacturing site.

India22China8Peru1Taiwan1Germany1Spain1South Korea1Country not recorded for 1
Need Celecoxib sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (28)

Certificates of Suitability on the EDQM register for Celecoxib, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 44 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
MATRIX PHARMACORP PRIVATE LIMITED SangareddyIN
CEP 2012-183 - Rev 07
Celecoxib
Nov 2026—
HARWAY PHARMA CO. LTD. DongyingCN
CEP 2024-373 - Rev 00
Celecoxib
Sept 2026—
HETERO DRUGS LIMITED HyderabadIN
CEP 2016-037 - Rev 03
Celecoxib
Aug 2026—
AARTI DRUGS LIMITED MumbaiIN
CEP 2014-199 - Rev 02
Celecoxib
Aug 2026—
INTERQUIM S.A. Sant Cugat Del VallesES
CEP 2026-220 - Rev 00
Celecoxib, Process 2
Jul 2026Inspected Sept 2024
Spain
DONGBANG FUTURE TECH & LIFE CO., LTD. Hwaseong-SiKR
CEP 2015-185 - Rev 01
Celecoxib
Mar 2026—
KEKULE PHARMA LIMITED HyderabadIN
CEP 2023-274 - Rev 01
Celecoxib, Micronised and non-micronised
Mar 2026—
AURORE LIFE SCIENCES PRIVATE LIMITED HyderabadIN
CEP 2023-194 - Rev 02
Celecoxib, Site Khazipally
Feb 2026—
ZHEJIANG CHEMSYN PHARM. CO., LTD. QuzhouCN
CEP 2020-170 - Rev 01
Celecoxib
Sept 2025—
MICRO LABS LIMITED BengaluruIN
CEP 2012-286 - Rev 02
Celecoxib
Jul 2025—
ALEMBIC PHARMACEUTICALS LIMITED VadodaraIN
CEP 2012-388 - Rev 04
Celecoxib
May 2025—
PHARMAZELL GMBH RaublingDE
CEP 2012-151 - Rev 03
Celecoxib
Feb 2025Inspected Jun 2025
Germany
JIANGXI SYNERGY PHARMACEUTICAL CO., LTD. YichunCN
CEP 2024-468 - Rev 00
Celecoxib, Process II
Feb 2025—
HIKAL LIMITED BangaloreIN
CEP 2017-199 - Rev 04
Celecoxib
Sept 2024Inspected Nov 2025
Switzerland
SCINOPHARM TAIWAN LTD. Shan-HuaTW
CEP 2016-320 - Rev 01
Celecoxib
Sept 2024—
AMOLI ORGANICS PRIVATE LIMITED MumbaiIN
CEP 2024-200 - Rev 00
Celecoxib, Process-III, Form-III
Aug 2024—
HENAN DONGTAI PHARM CO., LTD. Anyang CityCN
CEP 2022-283 - Rev 00
Celecoxib
May 2024—
IPCA LABORATORIES LIMITED MumbaiIN
CEP 2023-325 - Rev 00
Celecoxib
May 2024—
APITORIA PHARMA PRIVATE LIMITED HyderabadIN
CEP 2012-320 - Rev 02
Celecoxib
Jan 2024—
MACLEODS PHARMACEUTICALS LIMITED MumbaiIN
CEP 2015-195 - Rev 01
Celecoxib
Sept 2023—
CIPLA LIMITED MumbaiIN
R1-CEP 2014-186 - Rev 01
Celecoxib
May 2023—
SHANDONG ANXIN PHARMACEUTICAL CO., LTD. Dongjia TownCN
R1-CEP 2015-297 - Rev 01
Celecoxib
Aug 2022—
CADILA PHARMACEUTICALS LIMITED AnkleshwarIN
R1-CEP 2015-220 - Rev 00
Celecoxib
May 2022—
QUIMICA SINTETICA S.A. Alcala De HenaresES
R1-CEP 2016-160 - Rev 00
Celecoxib
Nov 2021—
Interquim, S.A. Sant Cugat Del VallèsES
R1-CEP 2012-351 - Rev 01
Celecoxib
Jul 2021—
ZENJI PHARMACEUTICALS (SUZHOU) LTD. Xuguan, SuzhouCN
R1-CEP 2015-029 - Rev 00
Celecoxib
Mar 2021—
RAKS PHARMA PVT. LTD. VisakhapatnamIN
R1-CEP 2013-317 - Rev 00
Celecoxib
Mar 2020—
JIANGXI SYNERGY PHARMACEUTICAL CO., LTD. FengxinCN
R1-CEP 2012-404 - Rev 00
Celecoxib
Jul 2019—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (3)

Organisations whose Type II DMFs for Celecoxib are no longer active. These show a past filing, not current supply.

Show all 3 historical records

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (73 listed products contain Celecoxib). The latest listed patent expires 17 Sept 2045. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2), leading to decreased formation of prostaglandins involved in inflammation and pain. It is commonly used to treat conditions such as osteoarthritis, rheumatoid arthritis, and acute pain.

Chemical identity

IUPAC name
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
Canonical SMILES
CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F
InChIKey
RZEKVGVHFLEQIL-UHFFFAOYSA-N
Synonyms
Celebrex API, celebrex, consensi component celecoxib, dfn-15, dfn15, elyxyb, nsc-719627, nsc-758624, onsenal, sc-58635

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Nonsteroidal Anti-inflammatory Drug
Mechanism of action
Cyclooxygenase Inhibitors
Chemical structure
Non-Steroidal

Therapeutic areas

PainInflammationArthritis

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Celecoxib?

36 organisations hold an active US FDA Type II Drug Master File or a CEP for Celecoxib: MICRO LABS LTD (India), AARTI DRUGS LTD (India), Alembic Pharmaceuticals Limited (India), APITORIA PHARMA PRIVATE LTD (India), Aurore Life Sciences (India), Cadila Pharmaceuticals Limited (India), Cipla Limited (India) and HENAN DONGTAI PHARM CO LTD (China), and 28 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Celecoxib Drug Master Files are active?

MICRO LABS LTD (DMF 24686, 37290), AARTI DRUGS LTD (DMF 23161), Alembic Pharmaceuticals Limited (DMF 24419), APITORIA PHARMA PRIVATE LTD (DMF 27501), Aurore Life Sciences (DMF 34070), Cadila Pharmaceuticals Limited (DMF 19155), Cipla Limited (DMF 16671) and HENAN DONGTAI PHARM CO LTD (DMF 37092) and 18 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Celecoxib records mean?

3 organisations have only inactive Type II DMFs for Celecoxib. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Celecoxib have a European Certificate of Suitability?

Yes. 26 organisations hold a valid CEP for Celecoxib on the EDQM register, including MATRIX PHARMACORP PRIVATE LIMITED Sangareddy (IN), HARWAY PHARMA CO. LTD. Dongying (CN), HETERO DRUGS LIMITED Hyderabad (IN), AARTI DRUGS LIMITED Mumbai (IN), INTERQUIM S.A. Sant Cugat Del Valles (ES) and DONGBANG FUTURE TECH & LIFE CO., LTD. Hwaseong-Si (KR) and 22 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Celecoxib?

Yes. The latest patent listed for an approved US product containing Celecoxib expires 17 Sept 2045, across 73 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Celecoxib supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Celecoxib?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.